Encore Dermatology, Inc. Announces Launch of HylatopicPlus® Lotion

MALVERN, Pa.--()--Encore Dermatology, Inc., a leader in developing and commercializing novel, prescription products for improving skin health, today announced the availability of HylatopicPlus® Lotion in a convenient 14 oz. bottle with pump dispenser. HylatopicPlus® Lotion is indicated to manage and relieve the burning, itching and pain experienced with various types of skin conditions, including atopic dermatitis (eczema), allergic contact dermatitis and radiation dermatitis. HylatopicPlus® Lotion also helps alleviate dry, waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process.

“With the addition of a 14 oz. bottle with its convenient pump dispensing mechanism, the HylatopicPlus® product line continues to expand, offering more treatment options for patients and clinicians”

“In order to combat the complex barrier defects appreciated in atopic dermatitis, a holistic approach is needed, one which includes all the elements necessary for dynamic skin functioning. These include a proper ratio of ceramides and fatty acids, humectants such as hyaluronic acid and glycerin to draw in water, and occlusive agents like dimethacone to help repair the skin barrier,” said Adam Friedman, MD, Associate Professor of Dermatology, Residency Program Director, Director of Translational Research, Department of Dermatology at George Washington School of Medicine and Health Sciences.

HylatopicPlus® Lotion was developed to add more versatility to the brand and to provide patients more treatment options when managing various types of dermatosis, including atopic dermatitis. The large HylatopicPlus® Lotion 14 oz. bottle is well-suited for those patients who are affected by eczema symptoms over a large surface area of their skin. The pump dispenser also helps avoid contamination of the product, even with repeated use.

“With the addition of a 14 oz. bottle with its convenient pump dispensing mechanism, the HylatopicPlus® product line continues to expand, offering more treatment options for patients and clinicians,” said Bob Moccia, President and CEO of Encore Dermatology. “The HylatopicPlus® product line, including HylatopicPlus® Cream and HylatopicPlus® Emollient Foam, is one of the most prescribed barrier therapies. We believe that the three key ingredients in the HylatopicPlus® line, hyaluronic acid, ceramides and the natural free fatty acids, may help patients see beneficial effects to the healing process of the skin barrier by maintaining a moist skin environment.”

HylatopicPlus® Lotion is available in the U.S. by prescription only.

Important Safety Information for HylatopicPlus® Lotion

HylatopicPlus® Lotion is contraindicated in persons with a known hypersensitivity to any of the components of the formulation. If clinical signs of infection are present, appropriate treatment should be initiated; use of HylatopicPlus® Lotion may be continued during the anti-infective therapy.

About Encore Dermatology, Inc.

Headquartered in Malvern, Pa., Encore Dermatology, Inc. is a privately held, fully integrated specialty dermatology company with a mission committed to delivering innovative prescription therapies and medical devices to dermatologists, while focusing on customer service and improving the quality of life of patients. In addition to the founders, principal investors are Essex Woodlands, 1315 Capital and Longitude Capital. For additional information, please visit www.encorederm.com.

ENC1123 10/16


Encore Dermatology, Inc.
Kent Taylor, 610-251-6960
VP Marketing

Encore Dermatology, Inc.